Brief: Altos Biologics Completes Patient Enrollment In Global Phase 3 Clinical Trial Of Eylea
22/02/2023 14:25
Feb 22 (Reuters) - Alteogen Inc 196170.KQ :
* ALTOS BIOLOGICS, A SUBSIDIARY OF ALTEOGEN, COMPLETED
PATIENT
ENROLLMENT IN GLOBAL PHASE 3 CLINICAL TRIAL OF EYLEA® BIOSIMILAR
IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Source text for Eikon: ID:nPn430Xjya
Further company coverage: 196170.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alteogen
See all newsBrief: Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics
Brief: Alteogen Signs Licensing Deal With Biogen International For Alt-B4
Brief: Alteogen 2025 Operating Profit 115 Billion Won, Up 275% From Year Earlier
Brief: Alteogen Signs $285 Million Contract With Gsk Unit
Brief: Alteogen Receives Positive CHMP Opinion For Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'